ArticleAnnals of medicine and surgery (2012)2025
Dissecting the role of metformin in urogenital malignancies.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin has shown great potential for anti-tumor therapy according to laboratory results, but there is currently no consensus on the role it playing in the pathogenesis of urogenital malignancies. Initially, a systematic review was conducted on clinical research examining the association between the use of metformin and the incidence and prognosis of prevalent urogenital malignancies. Then, a retrospective analysis of the participants in NHANES was performed to strengthen the study. Given the distinct methodological advantages of Mendelian randomization (MR) in research design, whereby genetic variations influencing the exposure of interest are independent of potential confounders, available GWAS data were thoroughly collected and utilized in a two-sample MR analysis to assess the causal relationships between metformin use and various urogenital malignancies. The review of literature demonstrated inconsistencies and ambiguities in clinical findings. The retrospective analysis of 20,527 participants in the NHANES did not reveal strong evidence in the four urogenital malignancies. The current MR study indicates that metformin use is unlikely to be a causal factor in the development of five urogenital malignancies (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.